Supplementary Materials

The PDF file includes:

  • Materials and Methods
  • Fig. S1. Intravenous nanoparticle localization and OTI activation in liver tissue after intravenous and intramuscular Np.APC-OVA administration.
  • Fig. S2. Schematic representation of prime and target vaccination regimen, efficacy, and immunogenicity.
  • Fig. S3. Total Pen+ CD8+ T cell numbers in the liver are not affected by FTY720 administration.
  • Fig. S4. T cell recruitment to the liver is dependent in part on the dose of PLGA-OVA administered.
  • Fig. S5. A prime and target approach protects mice against challenge with Tg P. berghei OVA-spz only when mice are vaccinated against OVA.
  • Fig. S6. Flow plots showing representative lymphocyte depletion after administration of depleting antibodies.
  • Fig. S7. Higher numbers of liver Pen+ CD8+ T cells correlated with greater protection after spz challenge.
  • Fig. S8. Histocytometric analysis of liver sections.
  • Fig. S9. Liver Pen+ CD8+ T cells preferentially home back to the liver in recipient mice.
  • Fig. S10. Gating strategy showing TRM phenotype of Pen+ T cells in the liver after nanoparticle administration and long-term efficacy data.
  • Fig. S11. Flow plots showing representative lymphocyte depletion and inhibition of egress from lymphatics after administration of depleting antibody and FTY720.
  • Fig. S12. A prime and target approach with viral vectors as targeting agents shows similar immunization profile to PLGA nanoparticle targeting.
  • Fig. S13. A prime and target approach with viral vectors generates high numbers of HBsAg CD8+ T cells in the liver.
  • Fig. S14. Safety and human immune responses to immunization with ChAd63.ME-TRAP-i.v.
  • Legend for movie S1

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Movie S1 (.mp4 format). Video showing the internalization of Np.APC-OVA within Kupffer cells.
  • Table S1 (Microsoft Excel format). Primary data file.
  • Data file S1 (.pdf format). Methodological information regarding clinical trial (NCT03084289).